1. Home
  2. CMTG vs PRLD Comparison

CMTG vs PRLD Comparison

Compare CMTG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Claros Mortgage Trust Inc.

CMTG

Claros Mortgage Trust Inc.

N/A

Current Price

$1.40

Market Cap

256.8M

Sector

Real Estate

ML Signal

N/A

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

N/A

Current Price

$3.19

Market Cap

260.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CMTG
PRLD
Founded
2015
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
256.8M
260.2M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
CMTG
PRLD
Price
$1.40
$3.19
Analyst Decision
Sell
Strong Buy
Analyst Count
6
5
Target Price
$1.87
★ $8.80
AVG Volume (30 Days)
★ 1.9M
243.3K
Earning Date
11-03-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 23.21
EPS
N/A
★ N/A
Revenue
★ $187,828,000.00
$12,140,000.00
Revenue This Year
N/A
$74.34
Revenue Next Year
N/A
$85.56
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 73.43
52 Week Low
$1.09
$1.30
52 Week High
$3.62
$6.83

Technical Indicators

Market Signals
Indicator
CMTG
PRLD
Relative Strength Index (RSI) 47.08 34.61
Support Level $1.09 $2.69
Resistance Level $1.92 $3.32
Average True Range (ATR) 0.14 0.29
MACD -0.01 -0.04
Stochastic Oscillator 33.14 2.53

Price Performance

Historical Comparison
CMTG
PRLD

About CMTG Claros Mortgage Trust Inc.

Claros Mortgage Trust Inc is a real estate investment trust. The company is focused mainly on creating a diversified portfolio of income-producing loans collateralized by institutional-quality commercial real estate.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Share on Social Networks: